POSC35 Venetoclax Combination Therapies Show Significant Improvements in Overall Survival and Remission in Treatment-Naïve Patients with AML Who Are Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

X Li,Hs Suh,J Lachaine,Ac Schuh,K Pratz,Ka Betts,J Song,C Gu,Cn Bui

doi:10.1016/j.jval.2021.11.181

POSC35 Venetoclax Combination Therapies Show Significant Improvements in Overall Survival and Remission in Treatment-Naïve Patients with AML Who Are Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

X Li, Hs Suh + Show 7 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.181

Copy DOI

Journal: Value in Health	Publication Date: Jan 1, 2022
License type: elsevier-specific: oa user license

Affiliation: Analysis Group (United States), China National Health Development Research Center, Hospital of the University of Pennsylvania, Princess Margaret Cancer Centre

#Acute Myeloid Leukemia Who #Best Supportive Care + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The aim of this network meta-analysis (NMA) was to assess the relative efficacy of venetoclax (VEN) plus azacitidine (AZA) and VEN plus low-dose cytarabine (LDAC) versus AZA, LDAC, decitabine, and best supportive care (BSC) only for adult patients with untreated acute myeloid leukemia (AML) deemed ineligible for intensive chemotherapy.

Full Text